Chronic Kidney Disease is an ailment related with debilitate of kidney work and the danger of kidney disappointment, typically in blend with various kidney infections including renal colic, and end stage renal illness, intense cylindrical putrefaction. Kidney disappointment happens because of one or the other essential or auxiliary harm to the kidneys from the development of scar tissue (plaque) due to scarring brought about by a kidney stone or different stores. Kidney stones are brought about by the development of uric corrosive gems inside the kidneys. There are various medications that can be utilized for the treatment of this sickness. One of these medications is called calcium channel blockers, which block the calcium directs in the kidneys.
The developing predominance of chronic kidney disease drugs all throughout the planet is a superb factor driving business sector development. As indicated by the National Kidney Foundation Inc., it influences an expected 37 million individuals in the U.S. (15% of the grown-up populace; more than 1 out of 7 grown-ups) and around 90% of those with CKD don't realize they have it. In 2017, more than 500,000 patients got dialysis treatment, and more than 200,000 lived with a kidney relocate. Additionally, the developing occurrence of diabetes is likewise projected to encourage market development. Besides, an ascent in worldwide medical care consumption combined with the increment in the geriatric populace as they are exceptionally inclined to such constant illness is additionally expected to cultivate the development of the chronic kidney disease drugs market.
The growing prevalence of chronic kidney disease drugs around the globe is a prime factor driving market growth. According to the National Kidney Foundation Inc., it affects an estimated 37 million people in the U.S. (15% of the adult population; more than 1 in 7 adults) and around 90% of those with CKD don’t even know they have it. In 2017, over 500,000 patients received dialysis treatment, and over 200,000 lived with a kidney transplant. Moreover, the growing incidence of diabetes is also projected to foster market growth. Furthermore, a rise in global healthcare expenditure coupled with the increase in the geriatric population as they are highly prone to such chronic disease is further expected to foster the growth of the chronic kidney disease drugs market.
North America is expected to gain significant growth over the forecast period and this is attributed to increasing medicare cost for treating chronic kidney disease in the region. According to the Centers for Disease Control and Prevention, overall Medicare costs for people with CKD were over $84 billion in 2017 or more than $22,000 per person.
Key Developments:
1. In August 2020, AstraZeneca India a science-led biopharmaceutical company announced the results from the clinical trials of its latest diabetes drug, dapagliflozin, showing significant benefits in reducing chronic kidney disease (CKD) progression in patients with and without type-2 diabetes.
2. In September 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its drug INVOKANA® (Canagliflozin) has been approved by the U.S. Food and Drug Administration (FDA). This drug is beneficial in reducing the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease (CKD).
No comments:
Post a Comment